A cross-sectional analysis that included 1378 HIV-uninfectedfemale participants aged 15-49 was conducted to investigate the association between hormonal contraceptive use and high-risk humanpapilloma virus (HR-HPV) prevalence in Rakai, Uganda. Hormonalcontraception (HC) use consisted of injectable DMPA (n=126), oralcontraception (n=25) and implants (n=3) in this study.The analysis was stratified by age into two groups 15 to 29 and 30to 49 years, because HR-HPV in the older women was most relevant tothe risk of cervical neoplasia. The overall prevalence rate of infectionwith HR-HPV decreased with older age for both the HC users (exposuregroup) and non-pregnant and non-HC users (reference group).The results showed that the use of hormonal contraceptive was notassociated with increased prevalence rate of HR-HPV after controllingfor other covariates including age, number of sexual partners in theprevious year, condom use in previous year, educational level and currentpregnancy or breastfeeding status. (Crude prevalence risk ratio(PRR)=1.064, P-value=0.57). After adjusting for other covariates in thelog-binomial model, the association between HC use and the risk ofinfection with HR-HPV was not statistically significant for the two agegroups. Female participants aged 15 to 29 had an adjusted PRR=1.043, Piiivalue=0.73 and participants aged 30 to 49 had an adjusted PRR=1.059with P-value=0.83.Conclusion: Hormonal contraceptive use by female participantswas not significantly associated with increased prevalence of infectionwith HR-HPV and the effect of interaction between HC use and age onthe risk of infection with HR-HPV is not statistically significant.More research is needed to examine the effect of HC use on HPVincidence and persistence.
【 预 览 】
附件列表
Files
Size
Format
View
The Association Between Female Hormonal Contraceptive Use and HPV Prevalence in Female Participants, Rakai, Uganda